MedTech research and development company Medinol Inc announced on Thursday that its subsidiary Microtech has started human clinical trials of its microsensor platform, in a trial to assess atrial pressures important for the treatment of heart failure.
The first implantation was recently conducted by Prof. Erez Sharoni at Beilinson Medical Centre in Petah-Tikva, Israel.
The Microtech implantable microsensor platform is the result of decades of development in a new class of sensor technology that can be used both as a stand-alone device or integrated with existing devices.
Prof. Sharoni, head of Cardio-Thoracic Surgery, said: "This amazing technology may change the standard of care for patients suffering from heart failure and in particular, in this current study, those who are receiving LVADs or heart transplants."
NanoVibronix completes pilot phase of UroShield study at University of Michigan
Hologic acquires Gynesonics for USD350m
Inogen secures FDA clearance for SIMEOX 200 Airway Clearance Device
Microtech commences human clinical trial of microsensor platform for heart failure
Defense Diagnostics launches DEFENT ONE All-In-One Fentanyl Detection Device in US
HeartBeam secures FDA clearance for innovative at-home heart monitoring device
Eli Lilly to expand Wisconsin facility
GC Biopharma and Novel Pharma report first patient dosed in multinational trial of GC1130A
Abbott launches first patient procedures with investigational TAVI system
SHL Medical to establish tooling and automation sub-group
Epigenic Therapeutics receives New Zealand approval for EPI-003 clinical trial
GRAIL reports first patient tested with blood-based assay in TROPION-Lung12 Phase 3 study